Core Viewpoint - The company has proposed a share incentive plan that requires approval from shareholders at a special general meeting before it can take effect [1] Group 1: Share Incentive Plan - The share incentive plan was decided by the board of directors on February 9, 2026 [1] - The maximum number of shares that can be granted under the plan is capped at 5.0% of the total issued shares of the company as of the adoption date, excluding any treasury shares, which amounts to 8.3799 million H-shares [1]

Group 1 - The company Wangshan Wangshui-B (02630.HK) announced a proposed adoption of a share award plan by its board of directors on February 9, 2026 [1] - The share award plan requires approval from shareholders at a special general meeting before it becomes effective [1] - Under the share award plan, the maximum number of shares that can be awarded is capped at 5.0% of the total issued shares of the company as of the adoption date, which amounts to 8,379,890 H-shares [1]

Group 1 - The company Wangshan Wangshui-B (02630) announced a proposed share incentive plan to be adopted by the board on February 9, 2026 [1] - The share incentive plan requires approval from shareholders at a special general meeting before it can take effect [1] - The maximum number of shares that can be granted under the plan is capped at 5.0% of the total issued shares of the company as of the adoption date, which amounts to 8.3799 million H-shares [1]

（於中華人民共和國註冊成立的股份有限公司） （股份代號：2630） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容引致的任何損失承擔任何責任。 Vigonvita Life Sciences Co., Ltd. 蘇州旺山旺水生物醫藥股份有限公司 建議採納H股股份獎勵計劃 蘇州旺山旺水生物醫藥股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 董事（「董事」）會（「董事會」）欣然宣佈，於2026年2月9日，董事會已議決建議採 納本公司股份獎勵計劃。股份獎勵計劃須經股東於股東特別大會上考慮及批准後 生效。 根據股份獎勵計劃，獎勵所涉及的H股將於聯交所購買及╱或透過場外交易取 得。於該計劃期間，根據股份獎勵計劃可授出的股份最高數目合共不得超過於採 納日期本公司已發行股份總數（不包括任何庫存股份）的5.0%，即8,379,890股H 股。 一般事項 股份獎勵計劃將構成上市規則第17章項下涉及現有股份的股份計劃，並須遵守上 市規則第17.12條項下的適用披露規定。然而，其並不構成上市規 ...

Group 1 - The core point of the article is that ST Huaxi (002630.SZ) announced the termination of a planned capital increase of 300 million yuan due to external factors and funding issues [1] - The company received a letter from Ningbo Huarui on February 5, 2026, indicating the decision to abandon the capital increase [1] - The capital increase agreement was not signed, and the decision was made after careful consideration of the implementation progress [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02630 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 66,677,133 | RMB | | 1 RMB | | 66,677,133 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 66,677,133 | RMB | | 1 RMB | | 66,677,133 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | ...

Group 1 - The stock of Wangshan Wangshui-B (02630) experienced a decline of nearly 7% after a previous increase of nearly 11%, currently trading at 101.4 HKD with a transaction volume of 11.0993 million HKD [1] - A significant research finding was published by the Wuhan Institute of Virology, confirming that the oral nucleoside drug VV116 has notable antiviral activity against the Nipah virus, providing new hope for the prevention and treatment of this highly lethal emerging infectious disease [1] - VV116, developed by Wangshan Wangshui, is an oral nucleoside drug with broad-spectrum antiviral potential, already approved for use against SARS-CoV-2 in China and Uzbekistan under the brand names Mindwei and Mindvy respectively [1] Group 2 - Industry expert Li Changcheng analyzed that if the efficacy of the drug against the Nipah virus is confirmed, pharmaceutical companies may expand the drug's usage, leading to greater commercial benefits, as extending indications on existing drugs incurs the lowest costs and highest returns [2] - It is noted that while there is theoretical support for nucleoside drugs inhibiting the Nipah virus, the effectiveness against the current Indian strain of the virus requires clinical validation [2]

Group 1 - The stock of Wangshan Wangshui-B (02630) experienced a decline of nearly 7% after a previous increase of nearly 11%, currently trading at 101.4 HKD with a transaction volume of 11.0993 million HKD [1] - A significant research finding was published by the Wuhan Institute of Virology, confirming that the oral nucleoside drug VV116 has notable antiviral activity against the Nipah virus, providing new hope for the prevention and treatment of this highly lethal emerging infectious disease [1] - VV116, developed by Wangshan Wangshui, is an oral nucleoside drug with broad-spectrum antiviral potential, already approved for use against SARS-CoV-2 in China (marketed as Mindwei®) and Uzbekistan (marketed as Mindvy®) [1] Group 2 - Industry expert Li Changcheng analyzed that if the efficacy of the drug against the Nipah virus is confirmed, pharmaceutical companies may expand the drug's usage, leading to greater commercial benefits, as extending indications on existing drugs incurs the lowest costs and yields the highest returns [2] - It is noted that while there is theoretical support for nucleoside drugs inhibiting the Nipah virus, the effectiveness against the current Indian strain of the virus requires clinical validation [2]

Core Viewpoint - The oral COVID-19 drug VV116 shows significant antiviral activity against the highly lethal Nipah virus, potentially providing a ready-made treatment option amid the absence of approved vaccines or specific therapies for Nipah virus infections [2][4][7]. Group 1: Research Findings - Recent studies published in the journal "Emerging Microbes & Infections" confirm that VV116 can increase the survival rate of infected golden hamsters to 66.7% and significantly reduce viral loads in key organs [4][6]. - The research indicates that VV116 exhibits notable inhibitory effects against two main strains of the Nipah virus, NiV-M and NiV-B, in vitro and in animal models [6][8]. - The Nipah virus has a mortality rate ranging from 32% to 70%, with recent outbreaks reported in India, raising public health concerns [6][7]. Group 2: Company Responses - Junshi Bioscience stated that they have not conducted similar research and that expanding indications would require clinical data support [2][12]. - In contrast, Wangshan Wangshui expressed their intent to closely monitor the epidemic's developments and initiate clinical trials for treatment or post-exposure prevention as needed [2][12]. Group 3: Market Impact - Following the announcement, Wangshan Wangshui's stock price surged nearly 15% during trading on January 27, closing at 108.9 HKD per share, marking a 10.90% increase and a historical high [3]. - Junshi Bioscience's stock also rose by 7.96% on the same day [3]. Group 4: Broader Implications - VV116, developed through collaboration among several Chinese research institutions, is positioned as a broad-spectrum antiviral drug with potential applications beyond COVID-19, including against other RNA viruses [8][10]. - The drug's mechanism targets the highly conserved RNA-dependent RNA polymerase (RdRp) of RNA viruses, suggesting its effectiveness against future viral variants [8][10]. Group 5: Financial Context - Wangshan Wangshui reported that VV116 generated significant revenue, accounting for 98% of the company's total revenue in 2023, but faces challenges as demand for COVID-19 treatments declines [13]. - The company has experienced financial losses in the post-pandemic era, with net losses of approximately 218 million CNY in 2024 and 112 million CNY in the first four months of 2025 [13].

Group 1: Nipah Virus Outbreak - The Nipah virus outbreak in West Bengal, India has confirmed 5 cases, with nearly 100 individuals under observation [1] - Neighboring countries like Thailand and Nepal have increased health screening measures for travelers from India [1] - The World Health Organization (WHO) states that Nipah virus is zoonotic and can be transmitted from infected animals to humans, with symptoms including acute respiratory infections and fatal encephalitis [1] Group 2: VV116 Drug Development - VV116 is an oral nucleoside drug with broad-spectrum antiviral potential, developed by Wangshan Wangshui and Junshi Biosciences [2][4] - Recent research published in the journal Emerging Microbes & Infections confirms that VV116 shows significant antiviral activity against the Nipah virus, providing new hope for treatment [1][6] - The drug has previously been approved for COVID-19 treatment in China and Uzbekistan, and its commercialization has significantly contributed to the company's revenue [4] Group 3: Market Response and Stock Performance - Following the announcement of VV116's potential against Nipah virus, Wangshan Wangshui's stock rose by 10.9%, reaching a new high since its listing in November 2025 [2] - Other companies in the IVD sector, such as Kaipu Bio and Da'an Gene, have also seen stock price increases due to their development of Nipah virus detection kits [9] - The market sentiment towards high-pathogenic virus detection has intensified, with multiple diagnostic companies reporting stock price gains [9] Group 4: Clinical and Regulatory Developments - VV116 has shown potential in animal models to improve survival rates against Nipah virus infections, indicating its possible use as a preventive treatment for high-risk populations [6] - The Chinese government has included Nipah virus in its health quarantine regulations, emphasizing the importance of rapid laboratory diagnostics for outbreak control [8] - Several companies have developed and announced their Nipah virus detection technologies, enhancing the diagnostic capabilities in response to the outbreak [8][9]